Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.

[1]  Y. Kluger,et al.  Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. , 2020, The Lancet. Oncology.

[2]  Y. Lievens,et al.  Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach? , 2019, Front. Med..

[3]  A. Mansfield,et al.  Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 , 2019, Annals of Oncology.

[4]  D. de Ruysscher,et al.  Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[6]  F. Cappuzzo,et al.  Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. , 2019, Lung cancer.

[7]  A. Bang,et al.  Immunotherapy and radiotherapy for metastatic cancers. , 2019, Annals of palliative medicine.

[8]  C. Ménard,et al.  MA08.11 Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC , 2018, Journal of Thoracic Oncology.

[9]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[10]  Gregory Riely,et al.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Toyoaki Hida,et al.  Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[13]  J. Patel,et al.  81OSafety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases , 2017 .

[14]  S. Ekman,et al.  Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies. , 2017, Cancer Treatment Reviews.

[15]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[16]  H. Nechushtan,et al.  Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. , 2016, Lung cancer.

[17]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[18]  S. Peters,et al.  The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. , 2016, Cancer treatment reviews.

[19]  F. Barlesi,et al.  Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  B. Yaremko,et al.  Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. , 2009, Clinical lung cancer.

[21]  A. Brichet,et al.  Pronostic factors of synchronous brain metastases from lung cancer. , 2001, Lung cancer.